<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> is a key drug in the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but it causes <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathies</z:e> in patients </plain></SENT>
<SENT sid="1" pm="."><plain>Goshajinkigan (GJG) is a Kampo medicine that is used for the treatments of several neurological symptoms including pain and numbness </plain></SENT>
<SENT sid="2" pm="."><plain>More recently, GJG has been reported to prevent the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in clinical studies </plain></SENT>
<SENT sid="3" pm="."><plain>No experimental study, however, has been conducted to date to determine the effect of GJG on pain behaviour in a rat model of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, the impact on the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> effect of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> remains unknown </plain></SENT>
<SENT sid="5" pm="."><plain>In the present study, we examined the effects of GJG on the <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> and anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in rodents </plain></SENT>
<SENT sid="6" pm="."><plain>Repeated administration of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> caused cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> from days 3 to 37 and mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> from days 21 to 28 </plain></SENT>
<SENT sid="7" pm="."><plain>Repeated administration of GJG prevented the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> but not mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> and <z:mp ids='MP_0005405'>axonal degeneration</z:mp> in rat sciatic nerve </plain></SENT>
<SENT sid="8" pm="."><plain>Single administration of GJG reduced both cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> and mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> after the development of <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, GJG did not affect the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> effect of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells-implanted mice </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that GJG relieves the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced cold <z:mp ids='MP_0005407'>hyperalgesia</z:mp> and mechanical <z:mp ids='MP_0003177'>allodynia</z:mp> without affecting anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, and, therefore, may be useful for the <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> in clinical practice </plain></SENT>
</text></document>